Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with adv

Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes..